Nutriband Management
Management criteria checks 3/4
Nutriband's CEO is Gareth Sheridan, appointed in Jan 2016, has a tenure of 8.33 years. total yearly compensation is $378.67K, comprised of 52.8% salary and 47.2% bonuses, including company stock and options. directly owns 16.68% of the company’s shares, worth $6.43M. The average tenure of the management team and the board of directors is 5.8 years and 5.8 years respectively.
Key information
Gareth Sheridan
Chief executive officer
US$378.7k
Total compensation
| CEO salary percentage | 52.8% |
| CEO tenure | 8.3yrs |
| CEO ownership | 16.7% |
| Management average tenure | 5.8yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
Is Nutriband (NASDAQ:NTRB) A Risky Investment?
Mar 31
Is Nutriband (NASDAQ:NTRB) Weighed On By Its Debt Load?
Sep 13Nutriband GAAP EPS of -$0.12, revenue of $0.5M
Sep 08Nutriband opens a new branch in Ecuador with plans to expand into the South American market
Jul 22Nutriband: Advancing Transdermal Delivery Of Injectable Drugs
Nov 01Does Nutriband (NASDAQ:NTRB) Have A Healthy Balance Sheet?
Oct 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jan 31 2024 | n/a | n/a | -US$5m |
| Oct 31 2023 | n/a | n/a | -US$5m |
| Jul 31 2023 | n/a | n/a | -US$5m |
| Apr 30 2023 | n/a | n/a | -US$5m |
| Jan 31 2023 | US$379k | US$200k | -US$4m |
| Oct 31 2022 | n/a | n/a | -US$7m |
| Jul 31 2022 | n/a | n/a | -US$7m |
| Apr 30 2022 | n/a | n/a | -US$7m |
| Jan 31 2022 | US$311k | US$149k | -US$6m |
| Oct 31 2021 | n/a | n/a | -US$5m |
| Jul 31 2021 | n/a | n/a | -US$3m |
| Apr 30 2021 | n/a | n/a | -US$3m |
| Jan 31 2021 | US$210k | US$60k | -US$3m |
| Oct 31 2020 | n/a | n/a | -US$2m |
| Jul 31 2020 | n/a | n/a | -US$2m |
| Apr 30 2020 | n/a | n/a | -US$3m |
| Jan 31 2020 | US$57k | US$42k | -US$3m |
| Oct 31 2019 | n/a | n/a | -US$2m |
| Jul 31 2019 | n/a | n/a | -US$2m |
| Apr 30 2019 | n/a | n/a | -US$3m |
| Jan 31 2019 | US$88k | US$88k | -US$3m |
Compensation vs Market: Gareth's total compensation ($USD378.67K) is below average for companies of similar size in the US market ($USD674.55K).
Compensation vs Earnings: Gareth's compensation has increased whilst the company is unprofitable.
CEO
Gareth Sheridan (33 yo)
8.3yrs
Tenure
US$378,672
Compensation
Mr. Gareth Sheridan has been Chief Executive Officer and Director of Nutriband Inc. since 2016. Mr. Sheridan founded Nutriband Ltd., in 2012 an Irish company which was acquired in 2016. Mr. Sheridan was na...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.3yrs | US$346.67k | 7.77% $ 3.0m | |
| Founder | 8.3yrs | US$378.67k | 16.68% $ 6.4m | |
| CFO & Chief Accounting Officer | 5.8yrs | US$274.98k | 0.25% $ 95.8k | |
| COO & President of 4P Therapeutics | 5.4yrs | US$236.49k | 0.46% $ 178.5k | |
| Chief Scientific Officer | 6yrs | no data | 0.35% $ 133.6k | |
| President of Pocono Pharmaceutical | no data | US$115.60k | no data | |
| Head of Active Intelligence | no data | no data | no data |
5.8yrs
Average Tenure
49yo
Average Age
Experienced Management: NTRB's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.3yrs | US$346.67k | 7.77% $ 3.0m | |
| Founder | 8.3yrs | US$378.67k | 16.68% $ 6.4m | |
| Independent Director | 4.9yrs | US$40.66k | 0.15% $ 57.5k | |
| Independent Director | 5.8yrs | US$32.31k | 0.13% $ 51.6k | |
| Independent Director | 5.8yrs | US$32.31k | 0.16% $ 62.8k | |
| Member of Advisory Board | no data | US$37.00k | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 2.3yrs | US$32.31k | 0.011% $ 4.3k |
5.8yrs
Average Tenure
46yo
Average Age
Experienced Board: NTRB's board of directors are considered experienced (5.8 years average tenure).